Inhibitors of protein convertase subtilisin/kexin 9 (PCSK9) and acute coronary syndrome (ACS): the state-of-the-art
G Iannuzzo, M Gentile, A Bresciani, V Mallardo… - Journal of Clinical …, 2021 - mdpi.com
Acute Coronary Syndrome (ACS) remains one of the most frequent causes of morbidity and
mortality in the world. Although the age-and gender-adjusted incidence of ACS is …
mortality in the world. Although the age-and gender-adjusted incidence of ACS is …
[HTML][HTML] Safety and effectiveness of evolocumab during acute and sub-acute phases of acute coronary syndrome (ACS): a systematic review and meta-analysis
AF Alzarroug, HK Al Gahtani, S Algahtani… - Cureus, 2023 - ncbi.nlm.nih.gov
Background: Coronary artery disease (CAD), manifested mainly as acute coronary
syndrome (ACS), continues to be a major cause of mortality globally and a significant …
syndrome (ACS), continues to be a major cause of mortality globally and a significant …
[HTML][HTML] PCSK9 inhibitors for acute coronary syndrome: the era of early implementation
H Chen, X Chen - Frontiers in Cardiovascular Medicine, 2023 - frontiersin.org
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, a new cholesterol-lowering
strategy, can decrease low-density lipoprotein cholesterol (LDL-C) levels by inhibiting …
strategy, can decrease low-density lipoprotein cholesterol (LDL-C) levels by inhibiting …
Effect of the early application of evolocumab on blood lipid profile and cardiovascular prognosis in patients with extremely high-risk acute coronary syndrome
Y Hao, Y Yang, Y Wang, J Li - International Heart Journal, 2022 - jstage.jst.go.jp
Proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors significantly reduce low-density
lipoprotein cholesterol (LDL-C) and improve the prognosis of patients with acute coronary …
lipoprotein cholesterol (LDL-C) and improve the prognosis of patients with acute coronary …
Eligibility for PCSK9 inhibitors based on the 2019 ESC/EAS and 2018 ACC/AHA guidelines
KC Koskinas, B Gencer, D Nanchen… - European journal of …, 2021 - academic.oup.com
Abstract Aims The 2018 American College of Cardiology (ACC)/American Heart Association
(AHA) and 2019 European Society of Cardiology (ESC)/European Atherosclerosis Society …
(AHA) and 2019 European Society of Cardiology (ESC)/European Atherosclerosis Society …
Eligibility for PCSK 9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) …
B Gencer, KC Koskinas, L Räber… - Journal of the …, 2017 - Am Heart Assoc
Background The American College of Cardiology (ACC) and European Society of
Cardiology/European Atherosclerosis Society (ESC/EAS) have recently published …
Cardiology/European Atherosclerosis Society (ESC/EAS) have recently published …
Proprotein convertase subtilisin/kexin type 9 inhibition after acute coronary syndrome or prior myocardial infarction
GG Schwartz, RP Giugliano - Current Opinion in Lipidology, 2022 - journals.lww.com
Proprotein convertase subtilisin/kexin type 9 inhibition aft... : Current Opinion in Lipidology
Proprotein convertase subtilisin/kexin type 9 inhibition after acute coronary syndrome or prior …
Proprotein convertase subtilisin/kexin type 9 inhibition after acute coronary syndrome or prior …
[HTML][HTML] Impact of early initiation of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with acute coronary syndrome: A systematic review meta-analysis
L Nagendra, K Mahajan, G Gupta, D Dutta - Indian Heart Journal, 2023 - Elsevier
Objective Scant data is available on the efficacy and safety of proprotein convertase
subtilisin/kexin type-9 inhibitors (PCSK9i) for early and rapid reduction of low-density …
subtilisin/kexin type-9 inhibitors (PCSK9i) for early and rapid reduction of low-density …
Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: Shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in …
N Katsiki, VG Athyros, DP Mikhailidis… - Metabolism-Clinical …, 2017 - metabolismjournal.com
Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors have been shown to
decrease low-density lipoprotein cholesterol (LDL-C) levels by about 60% on top of statin …
decrease low-density lipoprotein cholesterol (LDL-C) levels by about 60% on top of statin …
[HTML][HTML] Early initiation of evolocumab markedly reduces low-density lipoprotein cholesterol levels after myocardial infarction
T Okada, M Doi, T Miyoshi, K Nosaka, S Taya… - Cardiovascular …, 2020 - jacc.org
Early reduction of low-density lipoprotein cholesterol (LDL-C) levels with statins is
recommended for acute coronary syndrome (ACS) patients (1). However, the achievement …
recommended for acute coronary syndrome (ACS) patients (1). However, the achievement …